Cheng Chen

Author of D3S-001 in advanced solid tumors with KRAS G12C mutations: a phase 1 trial in Nature Medicine. Read here:

[Hidehito HORINOUCHI @HHorinouchi]

🆙 #ASCO26 #LCSM Clinical Science Symposium
🔥Elisrasib (D3S-001, GDP-Bound KRAS G12C-i) as 1L Tx in KRAS G12C+ NSCLC
✅Mono: ORR 78%
✅+pembro: ORR 81.2%; PD-L1≥50%: ORR 95%
🎙️Dr. Shun Lu
🔢8511
☑️NCT05410145
🔗 https://t.co/CyYzbmbAMY
@OncoAlert @Larvol @ASCO @KRASKickers

[Joshua Reuss @Joshua_Reuss]

Dr. @BrunaPellini deftly discusses pembrolizumab/divarasib, elisrasib, and elisrasib/pembrolizumab in KRAS G12C+ NSCLC. Very promising efficacy but MUST balance against toxicity. Patient selection will be key here.

[Dr. Estela Rodriguez @Latinamd]

#ASCO26 Dr Shun Lu presents on #Elisrasib KRASG12C+IO combination
➡️ Elisrasib mono
ORR 78%- 68.3% confirmed
➡️ Elisrasib +IO
ORR 66.7% confirmed
⚠️ AEs: GI, LFTs
#lcsm

[Jordi Remon @JordiRemon]

1stL in KRASG12Cmut NSCLC will be crowded and complex. Elisrasib, another KRASG12Coff inh, reported activityn in 1stL alone and combo with pembro. Next future: how to decide intensification? Based on PDL1, comut, brain met status🤯.Will not be easy!! To icity is a concern #ASCO26

[Mario Balsa @MarioBalsaMD]

🫁 D3S-001: first-line elisrasib ± pembrolizumab in KRAS G12C-mutant NSCLC #ASCO26

🎯 Elisrasib monotherapy: ORR 78.0%, mPFS 12.4 months, 12-month OS 90%
💥 Elisrasib + pembrolizumab: ORR 81.3%, mPFS not reached, 12-month OS 88.8%
⚡ Responses were rapid, with most responders achieving response by week 6
🚨 Higher grade ≥3 TRAEs with the combination (32.7%)

The response rates are elis-rising…now we wait to see whether phase III data can truly KRAS the finish line 😉 #ASCO26

@OncoAlert @OncoReporte
@ASCO @_SEOM @LungCancerRx @Lung_Cancers

[Roberto Ferrara @RobertoFerrara_]

Brave study with elisrasib a novel KRAS G12off inhibitor as monotherapy in first line setting regardless of PD-L1. ORR >60% in all PD-L1 categories. PFS promising. G3 tox 7%
Elisrasib active on common mechanisms of resistance to other KRAS inhibitors (such KRAS amp).
#ASCO2026

[LUNGevity Foundation @LUNGevity]

A next-generation KRAS G12C inhibitor, elisrasib, showed promising first-line activity in advanced KRAS G12C-mutant NSCLC, both alone and with pembrolizumab. Response rates were 78% with monotherapy and 84.6% with the combination, with especially strong activity in tumors with high PD-L1 expression.

These are early results point to a potential new treatment option on the horizon for a common lung cancer driver mutation -- but there is work to be done. Larger studies should aim to confirm the benefit and find ways to improve safety. #ASCO26 #NSCLC #lungcancer #KRAS

[Stephen V Liu, MD @StephenVLiu]

#ASCO26 Safety quite reassuring. Monotherapy G3+ TRAE 7% with 9% dose interruption and no discontinuation. Elisrasib + pembro combo shows 10% pembro discontinuation from TRAE. With combo, note LFT elevation but primarily low grade with AST/ALT elevated but not bilirubin.

[Stephen V Liu, MD @StephenVLiu]

#ASCO26 1L elisrasib + pembroizumab in KRAS G12C NSCLC with RR 81% with DCR 98%, mDOR NR with 73% at 12m, mPFS NR with 54% at 12m and 12m OS rate 89%. Illustrative cases showing rapid, deep responses including CNS responses.

[Stephen V Liu, MD @StephenVLiu]

Dr. Shun Lu #ASCO26: first-line elisrasib (D3S-001) +/- pembrolizumab in KRAS G12C NSCLC, global study. With elirasib monotherapy, RR 78% with early suggestion of durability. Median DOR NR but 53% at 1 year and mPFS 12.4m with 12m OS rate 90%. Impressive early data.

[LARVOL @Larvol]

With @AACR 2026 abstracts out, we asked leading AI models to identify the most anticipated trials in oncology, here’s their combined ranking.

Early-phase KRAS-targeted programs like RMC-9805-001 (zoldonrasib) and D3S-001-100 (elisrasib) rise to the top, alongside first-in-human approaches and novel pathway-driven strategies.

The list highlights strong momentum in:
▶️ Next-generation KRAS inhibition (G12D and G12C)
▶️ Cell cycle and synthetic lethality targets (PKMYT1, WEE1, RB pathway)
▶️ Emerging immunotherapy combinations and novel targets like CCR8 and B7-H3

Together, these studies reflect how the field is advancing through early clinical innovation, novel mechanisms, and biomarker-driven strategies heading into AACR 2026.

Which study are you watching most closely?

Explore more insights and data from #AACR26 👉 https://t.co/bMhp9sykLc

#LARVOL #AACR2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @DrJNaidoo | @dr_yakupergun | @HHorinouchi | @MPishvaian

[Lung Cancers Today @Lung_Cancers]

🫁 Elisrasib showed “robust and durable efficacy” in patients with previously treated locally advanced or metastatic KRAS G12C NSCLC, according to results from an ongoing phase 1/2 trial presented at #AACR26 by @cbcbc1971.

➡️ Read more: https://t.co/wMOlsArHKg

#lcsm #NSCLC

[Young Kwang Chae, MD, MPH, MBA @youngkwangchae]

Encouraging results from #AACR26 on Elisrasib (D3S-001) for KRAS G12C NSCLC by Dr. Cho 🧬
Key highlights:
✅ 2L+ G12Ci Naïve: 59.5% ORR, mDOR 14.9 months.
✅ 3L+ G12Ci Refractory: 32.3% PR rate, mDOR 15.6 months.
✅ Mechanism: CNS penetrable; overcomes resistance in G12Ci-refractory settings.
✅ Safety: Favorable profile with consistent, manageable results.
With FDA Breakthrough Therapy and Fast Track designations, this next-gen inhibitor is moving to pivotal trials for both monotherapy and combination settings. 🚀📈
@AACR @KRASKickers @cbcbc1971 @yonsei_u @OncoAlert

[Stephen V Liu, MD @StephenVLiu]

Dr. Byoung Chul Cho presented elisrasib (D3S-001), next gen KRAS G12C inhibitor in NSCLC at #AACR26. Images not posted by request. In 84 pts with no prior G12C inhibitor, RR 59.5%, DCR 98.8%, PFS 9.4m. In pts with prior G12Ci, RR 32.3%, DCR 83.9% DOR 15.6, PFS 8.1m. ctDNA clearance in 80% of pts. In KRAS G12C with STK11/KEAP1 co-mutation, RR 55% (vs 76% in wild type). Safety reassuring: AST/ALT elevations in 10-13%, only 1 case of G3 each.

[AACR @AACR]

Byoung Chul Cho shared updated phase I/II clinical trial results evaluating elisrasib in patients with locally advanced or metastatic NSCLC at #AACR26. Learn more in AACR Annual Meeting News: https://t.co/zDWUL0UnRx

[Cheng Chen @ChengChen1228]

Elisrasib (G12C-OFF inhibitor) is showing promising results in 2L+ PDAC.
- Efficacy at RP2D 600mg QD:
65.00% uORR, 13.5 months mPFS
- Safety:
Only 8.7% Grade 3+ TRAEs, zero Grade 4/5 events

#PDAC #KRAS #G12C #Elisrasib #AACR

[OncLive.com @OncLive]

D3S-001 Receives FDA Breakthrough Therapy, Orphan Drug Designations in Select KRAS G12C-Mutant Solid Tumors
@US_FDA #NSCLC #colorectalcancer
https://t.co/B49mnmaC6X

[CUHK Medicine @CUHKMedicine]

A multinational study @NatureMedicine led by CU Medicine proved that D3S-001, a next-generation KRAS-G12C inhibitor developed in mainland China, showed promising results in treating various types of solid tumours in terms of anti-tumour activity, safety and tolerability. https://t.co/iRPyl6cDdL

📖: https://t.co/CgHEyL7hni

@TonyMok9 @herbloong

[NatureRevClinOncol @NatRevClinOncol]

New online! Next-generation KRAS-G12C inhibitor D3S-001 shows promise https://t.co/ehVWHgkp4J